Science and Technology Production

Bone - Comparative study of vitamin D2 and D3 pharmacokinetics

Congreso

Authorship:

Seijo M ; MASTAGLIA, SILVINA ROSANA ; Brito GM ; Keller GA ; Somoza J ; Diez RA ; DiGirolamo ; Oliveri B

Date:

2011

Publishing House and Editing Place:

ELSEVIER

ISSN:

8756-3282

Summary *

Some studies found cholecalciferol (D3) to be superior to ergocalciferol (D2) based on the effect of increasing or maintaining serum 25-hidroxyvitamin-D (25OHD) levels. The aim of this study was to compare D2 and D3 pharmacokinetics. We carried out a single-blind, placebo-controlled randomized trial during 11 weeks (Sept–Dec 2010) in Buenos Aires city. Young healthy volunteers (n=33) with an age of (X±SD) 33.4±6 years were included and divided into groups: D2 (n=11); D3 (n=11) and placebo (n=11). In the D groups the subjects received 100,000 IU (baseline) and 4,800 IU/day (d) of the vitamin D allocated from 7 to 21 d and no vitamin D, from22 to 77 d. The serum samples were obtained at basal and d: 3, 7, 14, 21, 35, 49, 63 and 77. Baseline 25OHD (ng/ml) levels were: D2: 16.3±7; D3: 24.2±6 (p<0.01) and placebo: 22.6±7. Placebo values of 25OHD did not increase over treatment, vitamin D administration augmented serum 25OHD levels in each sampling point. To take into account variability in basal 25OHD serum levels, subtraction of basal values was performed before pharmacokinetic analysis. For D3-treated subjects, AUC was 1107±481 ng·d/ml (range(r) 331–1920, 95%CI 823–1391), ke−0.246±0.104 day−1 (r:−0.479 to−0.125, 95% CI −0.307 to −0.185) and t½ 3.267±1.274 days (r: 1.448–5.545, 95%CI 2.514–4.020). For D2-treated subjects AUC was 1005±352 ng·d/ml (r: 638–1784, 95%CI 797–1213), ke −0.321±0.245 day−1 (r: −0.911 to −0.107, 95%CI −0.466 to −0.176) and t½ 3.105± 1.658 days (r: 0.761–6.469, 95%CI 2.124–4.085). Under this administration scheme, no pharmacokinetic differences were found between the two treatments and D2 was equally effective as D3 in raising and maintaining 25OHD levels. Information provided by the agent in SIGEVA

Key Words

Vitamina D Farmacocinetica Suplementación